Catalyst Pharmaceuticals achieved record revenues in Q4 2025, reaching $152.6 million, a 7.6% increase year-over-year. Growth was primarily driven by FIRDAPSE and the continued market uptake of AGAMREE, despite the entry of generic competitors for FYCOMPA. The company ended the year with a strong cash position of $709.2 million and provided optimistic 2026 guidance.
Q4 2025 total revenues reached $152.6 million, up 7.6% year-over-year, fueled by FIRDAPSE and AGAMREE growth.
FIRDAPSE Q4 revenue grew 18.3% to $97.6 million, while AGAMREE Q4 revenue surged 67.5% to $35.3 million.
FYCOMPA revenue declined to $19.6 million in Q4 due to the entry of multiple generic versions during the quarter.
The company announced a $200 million share repurchase program and has repurchased approximately $39.9 million to date.
Catalyst expects 2026 total revenues between $615 million and $645 million, driven by continued growth in FIRDAPSE and AGAMREE.
Analyze how earnings announcements historically affect stock price performance